Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible

Clin Transplant. 2009 Jan-Feb;23(1):140-5. doi: 10.1111/j.1399-0012.2008.00953.x.

Abstract

Patient KW, a 36-yr-old male renal transplant recipient, received transplant acceptance-inducing cells (TAICs) as an adjunct immunosuppressive therapy. In the weeks post-transplantation, the patient's conventional immunosuppressive treatment was gradually minimized, such that, from the 21st wk post-transplantation onwards, the patient was stably maintained on tacrolimus monotherapy. Treatment with TAICs was without complication, both at the time of administration and in the four-yr follow-up period. It is concluded that the production and administration of TAICs to recipients of kidney transplants from deceased donors is technically feasible.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cadaver
  • Cell- and Tissue-Based Therapy*
  • Feasibility Studies
  • HLA Antigens / immunology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / immunology*
  • Male
  • Tacrolimus / therapeutic use
  • Tissue Donors*
  • Transplantation Conditioning
  • Transplantation Tolerance / immunology*

Substances

  • HLA Antigens
  • Immunosuppressive Agents
  • Tacrolimus